Savient Pharmaceuticals to Provide Business Update on November 7, 2005

Savient Pharmaceuticals Inc. (NASDAQ: SVNTE), an
emerging specialty pharmaceuticals company focused on developing,
manufacturing and marketing novel therapeutic products for unmet
medical needs, announced today that it will issue a business update on
Monday, November 7, 2005.
   Christopher Clement, President and Chief Executive Officer, will
host a conference call on, November 7, 2005 at 11:00 a.m. EST. A live
webcast of the conference call can be accessed from the Webcast page
under the News section of the Company's website at
www.savientpharma.com.
   A replay of the webcast will be available on Savient
Pharmaceuticals' website through November 21, 2005. In addition, a
telephonic replay will be available through November 21, 2005. The
replay numbers are [phone] for domestic callers and (706)
645-9291 for international callers. The replay access code is 1996046.

   About Savient Pharmaceuticals, Inc.

   Based in East Brunswick, New Jersey, Savient Pharmaceuticals, Inc.
is a specialty pharmaceutical company dedicated to developing,
manufacturing and marketing novel therapeutic products that address
unmet medical needs. The Company's lead product development candidate,
Puricase(R), for the treatment of refractory gout has reported
positive Phase 1 and 2 clinical data. Savient's experienced management
team is committed to advancing its pipeline and expanding its product
portfolio by in-licensing late stage compounds and exploring
co-promotion and co-development opportunities that fit the Company's
expertise in specialty pharmaceuticals and initial focus in
rheumatology. The Company's operations also include a wholly-owned
U.K. subsidiary, Rosemont Pharmaceuticals Ltd., which develops,
manufactures and markets liquid formulations of prescription
pharmaceutical products. Rosemont's product portfolio includes over 90
liquid formulations primarily targeting the geriatric population.
Further information on the Company can be accessed by visiting
www.savientpharma.com.

   Safe Harbor Statement 

   This news release contains forward-looking statements within the
meaning of Section 21E of the Securities Exchange Act of 1934. All
statements, other than statements of historical facts, included in
this report regarding the Company's strategy, expected future
financial position, discovery and development of products, strategic
alliances, competitive position, plans and objectives of management
are forward-looking statements. Words such as "anticipate," "believe,"
"estimate," "expect," "intend," "plan," "will" and other similar
expressions help identify forward-looking statements, although not all
forward-looking statements contain these identifying words. These
forward-looking statements involve substantial risks and uncertainties
and are based on current expectations, assumptions, estimates and
projections about the Company's business and the biopharmaceutical and
specialty pharmaceutical industries in which the Company operates.
Such risks and uncertainties include, but are not limited to,
delisting of the Company's common stock from The Nasdaq Stock Market,
delay or failure in developing Prosaptide(TM), Puricase(R) and other
product candidates; difficulties of expanding the Company's product
portfolio through in-licensing; introduction of generic competition
for Oxandrin(R); fluctuations in buying patterns of wholesalers;
potential future returns of Oxandrin or other products; our continuing
to incur substantial net losses for the foreseeable future;
difficulties in obtaining financing; potential development of
alternative technologies or more effective products by competitors;
reliance on third-parties to manufacture, market and distribute many
of the Company's products; economic, political and other risks
associated with foreign operations; risks of maintaining protection
for the Company's intellectual property; risks of an adverse
determination in on-going or future intellectual property litigation;
and risks associated with stringent government regulation of the
biopharmaceutical and specialty pharmaceutical industries. The Company
may not actually achieve the plans, intentions or expectations
disclosed in its forward-looking statements, and you should not place
undue reliance on the Company's forward-looking statements. Actual
results or events could differ materially from the plans, intentions
and expectations disclosed in the forward-looking statements that the
Company makes. The Company's forward-looking statements do not reflect
the potential impact of any future acquisitions, mergers,
dispositions, joint ventures or investments that the Company may make.
The Company does not assume any obligation to update any
forward-looking statements.